These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30707505)

  • 1. Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics.
    Ogasawara K; Alexander GC
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):914-921. PubMed ID: 30707505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics.
    Ogasawara K; Breder CD; Lin DH; Alexander GC
    Clin Ther; 2018 Jan; 40(1):95-102.e2. PubMed ID: 29273471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
    Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
    Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
    Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D
    Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-infective agents, biologics, and vaccines approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research in 1993.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):908. PubMed ID: 8031072
    [No Abstract]   [Full Text] [Related]  

  • 7. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
    Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
    JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration.
    Liu XI; Dallmann A; Wang YM; Green DJ; Burnham JM; Chiang B; Wu P; Sheng M; Lu K; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2019 Aug; 59(8):1130-1143. PubMed ID: 30865317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demystifying the U.S. Food and Drug Administration: I. Understanding agency structure and function.
    Levi B; Lisiecki J; Rubin P; D'Amico RA; Hume KM; Seward B; Cederna PS
    Plast Reconstr Surg; 2014 Jun; 133(6):1495-1501. PubMed ID: 24867731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics: an update and challenge of their pharmacokinetics.
    Shi S
    Curr Drug Metab; 2014 Mar; 15(3):271-90. PubMed ID: 24745789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
    Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
    J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    G de la Torre B; Albericio F
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IOM Review of FDA--approved biologics labeled or studied for pediatric use.
    Field MJ; Ellinger LK; Boat TF
    Pediatrics; 2013 Feb; 131(2):328-35. PubMed ID: 23319521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.
    Guinn D; Madabushi R; Wang YM; Brodsky E; Zineh I; Maxfield K
    Ther Innov Regul Sci; 2020 Nov; 54(6):1363-1371. PubMed ID: 33258100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of FDA-approved biologics medicines.
    Kinch MS
    Drug Discov Today; 2015 Apr; 20(4):393-8. PubMed ID: 25220442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The history of regulatory system for plasma fractionation products in the United States].
    Fukuzawa M; Tsutani K
    Yakushigaku Zasshi; 2014; 49(2):205-13. PubMed ID: 25799842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.